Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Front Immunol. 2021 Feb 1;11:624971. doi: 10.3389/fimmu.2020.624971. eCollection 2020.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune cell abnormalities which lead to the production of autoantibodies and the deposition of immune complexes. Interleukin (IL)-17-producing cells play an important role in the pathogenesis of the disease, making them an attractive therapeutic target. Studies in lupus-prone mice and of cells from patients with SLE humans have shown that IL-17 represents a promising therapeutic target. Here we review molecular mechanisms involved in IL-17 production and Th17 cell differentiation and function and an update on the role of IL-17 in autoimmune diseases and the expected usefulness for targeting IL-17 therapeutically.
系统性红斑狼疮（SLE）是一种自身免疫性疾病，其特征为免疫细胞异常，导致自身抗体产生和免疫复合物沉积。白细胞介素（IL）-17 产生细胞在疾病发病机制中起重要作用，使其成为有吸引力的治疗靶点。狼疮易感小鼠的研究和 SLE 患者的细胞研究表明，IL-17 代表了一个有前途的治疗靶点。在这里，我们回顾了 IL-17 产生和 Th17 细胞分化和功能的分子机制，并更新了 IL-17 在自身免疫性疾病中的作用以及针对 IL-17 进行治疗的预期效果。
Zotero 插件